Patents by Inventor Ronald Edward Steele
Ronald Edward Steele has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11992479Abstract: The present invention relates to a composition for use in the treatment of a disease or disorder, wherein said disease or disorder is preferably a disease or disorder in which aldosterone overexposure contributes to the symptoms of said disease or disorder, said composition comprises a compound which is (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine or a pharmaceutically acceptable salt thereof, wherein preferably said compound is (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazolium[1,5-a]pyridine dihydrogen phosphate, and wherein said compound has an enantiomeric excess (ee) of the (R) form higher than or equal to 97%, and wherein said composition is administered once daily to a subject in need thereof.Type: GrantFiled: May 2, 2019Date of Patent: May 28, 2024Assignee: DAMIAN PHARMA AGInventors: Ronald Edward Steele, Christoph Schumacher
-
Publication number: 20230047158Abstract: The present invention relates to a compound selected from (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine and a pharmaceutically acceptable salt thereof, and in particular to the phosphate salt of (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine, both having preferably an enantiomeric excess of the (R) form higher than or equal to 97%. Furthermore, the present invention relates to pharmaceutical compositions comprising the same, their use as a medicament and in methods of treatment of diseases and disorders in humans including women of child bearing potential and pediatric patients in which aldosterone over-exposure contributes to the deleterious effects of said diseases or disorders, as well as processes for preparing said inventive compounds.Type: ApplicationFiled: August 9, 2022Publication date: February 16, 2023Inventors: Christoph SCHUMACHER, Walter FUHRER, Ronald Edward STEELE
-
Patent number: 11447491Abstract: The present invention relates to a compound selected from (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine and a pharmaceutically acceptable salt thereof, and in particular to the phosphate salt of (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine, both having preferably an enantiomeric excess of the (R) form higher than or equal to 97%. Furthermore, the present invention relates to pharmaceutical compositions comprising the same, their use as a medicament and in methods of treatment of diseases and disorders in humans including women of child bearing potential and pediatric patients in which aldosterone over-exposure contributes to the deleterious effects of said diseases or disorders, as well as processes for preparing said inventive compounds.Type: GrantFiled: August 12, 2020Date of Patent: September 20, 2022Assignee: DAMIAN PHARMA AGInventors: Christoph Schumacher, Walter Fuhrer, Ronald Edward Steele
-
Publication number: 20210169861Abstract: The present invention relates to a composition for use in the treatment of a disease or disorder, wherein said disease or disorder is preferably a disease or disorder in which aldosterone overexposure contributes to the symptoms of said disease or disorder, said composition comprises a compound which is (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine or a pharmaceutically acceptable salt thereof, wherein preferably said compound is (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazolium[1,5-a]pyridine dihydrogen phosphate, and wherein said compound has an enantiomeric excess (ee) of the (R) form higher than or equal to 97%, and wherein said composition is administered once daily to a subject in need thereof.Type: ApplicationFiled: May 2, 2019Publication date: June 10, 2021Inventors: Ronald Edward STEELE, Christoph SCHUMACHER
-
Publication number: 20210024519Abstract: The present invention relates to a compound selected from (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine and a pharmaceutically acceptable salt thereof, and in particular to the phosphate salt of (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine, both having preferably an enantiomeric excess of the (R) form higher than or equal to 97%. Furthermore, the present invention relates to pharmaceutical compositions comprising the same, their use as a medicament and in methods of treatment of diseases and disorders in humans including women of child bearing potential and pediatric patients in which aldosterone over-exposure contributes to the deleterious effects of said diseases or disorders, as well as processes for preparing said inventive compounds.Type: ApplicationFiled: August 12, 2020Publication date: January 28, 2021Inventors: Christoph SCHUMACHER, Walter FUHRER, Ronald Edward STEELE
-
Patent number: 10822332Abstract: The present invention relates to a compound selected from (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine and a pharmaceutically acceptable salt thereof, and in particular to the phosphate salt of (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine, both having preferably an enantiomeric excess of the (R) form higher than or equal to 97%. Furthermore, the present invention relates to pharmaceutical compositions comprising the same, their use as a medicament and in methods of treatment of diseases and disorders in humans including women of child bearing potential and pediatric patients in which aldosterone over-exposure contributes to the deleterious effects of said diseases or disorders, as well as processes for preparing said inventive compounds.Type: GrantFiled: October 26, 2017Date of Patent: November 3, 2020Assignee: DAMIAN PHARMA AGInventors: Christoph Schumacher, Walter Fuhrer, Ronald Edward Steele
-
Publication number: 20190292180Abstract: The present invention relates to a compound selected from (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine and a pharmaceutically acceptable salt thereof, and in particular to the phosphate salt of (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine, both having preferably an enantiomeric excess of the (R) form higher than or equal to 97%. Furthermore, the present invention relates to pharmaceutical compositions comprising the same, their use as a medicament and in methods of treatment of diseases and disorders in humans including women of child bearing potential and pediatric patients in which aldosterone over-exposure contributes to the deleterious effects of said diseases or disorders, as well as processes for preparing said inventive compounds.Type: ApplicationFiled: October 26, 2017Publication date: September 26, 2019Applicant: DAMIAN PHARMA AGInventors: Christoph SCHUMACHER, Walter FUHRER, Ronald Edward STEELE
-
Publication number: 20040204444Abstract: The invention relates to a pharmaceutical composition, of (i) an aldosterone synthase inhibitor or a pharmaceutically acceptable salt thereof either alone or in combination with (ii) an AT1-receptor antagonist combined with a diuretic, or in each case, a pharmaceutically acceptable salt thereof and (iii) a pharmaceutically acceptable carrier.Type: ApplicationFiled: April 15, 2004Publication date: October 14, 2004Inventor: Ronald Edward Steele
-
Publication number: 20030083342Abstract: The invention relates to a pharmaceutical composition, of (i) an aldosterone synthase inhibitor or a pharmaceutically acceptable salt thereofeither alone or in combination with (ii) an AT1-receptor antagonist combined with a diuretic, or in each case, a pharmaceutically acceptable salt thereof and (iii) a pharmaceutically acceptable carrier.Type: ApplicationFiled: August 27, 2002Publication date: May 1, 2003Inventor: Ronald Edward Steele
-
Patent number: 5981006Abstract: A coupled spin-draw process for making a fully-oriented nylon yarn including extruding molten nylon polymer with a selected RV through a spinneret and cooling to produce a yarn. The yarn is withdrawn from the quench zone with a feed roll rotating at a speed of at least 4500 mpm. The process further includes cold drawing followed by relaxing the yarn using a steam intermingling jet and then winding up.Type: GrantFiled: March 11, 1997Date of Patent: November 9, 1999Assignee: E.I. du Pont de Nemours and CompanyInventors: Walter John Jaegge, Francis Joseph Malone, Jr., Frank Hudson Overton, Roger Allen Ross, Ronald Edward Steele
-
Patent number: 5750215Abstract: A coupled spin-draw process for making a fully-oriented nylon yarn including extruding molten nylon polymer with a selected RV through a spinneret and cooling to produce a yarn. The yarn is withdrawn from the quench zone with a feed roll rotating at a speed of at least 4500 mpm. The process further includes cold drawing followed by relaxing the yarn using a steam intermingling jet and then winding up.Type: GrantFiled: March 11, 1997Date of Patent: May 12, 1998Assignee: E. I. du Pont de Nemours and CompanyInventors: Walter John Jaegge, Francis Joseph Malone, Jr., Frank Hudson Overton, Roger Allen Ross, Ronald Edward Steele